A3 adenosine receptors: Protective vs. damaging effects identified using novel agonists and antagonists

Drug Development Research

Volumn 45, Issue 3-4, 1998, Pages 113-124

  Jacobson, Kenneth A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

A3 receptors; Cell viability; Dihydropyridines; Molecular modeling; Purines; Pyridines

Indexed keywords

1,4 DIHYDRO 2 METHYL 6 PHENYL 4 (2 PHENYLETHYNYL) 3,5 PYRIDINEDICARBOXYLIC ACID 5 BENZYL 3 ETHYL ESTER; 1,4 DIHYDROPYRIDINE DERIVATIVE; 2 CHLORO 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; 5 BENZYL 3 ETHYL 2 METHYL 6 PHENYL 4 PHENYLETHYNYL 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLIC ACID; 6 ETHYL 4 PROPYL 2 PHENYL 3 PYRIDINECARBOXYLIC ACID 5 THIOCARBOXYLIC ACID 5 ETHYL 3 PROPYL ESTER; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; 6 N (4 AMINOBENZYL) ADENOSINE 5' N METHYLURONAMIDE; 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; MRS 1067; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ASTHMA; CELL PROTECTION; CONFERENCE PAPER; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; INFLAMMATION; MOLECULAR MODEL; NONHUMAN; RECEPTOR DOWN REGULATION; SECOND MESSENGER; STRUCTURE ACTIVITY RELATION;

EID: 0032468791     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199811/12)45:3/4<113::AID-DDR5>3.0.CO;2-S     Document Type: Conference Paper

References (63)

1. 3 receptors in rat brain. Mol Pharmacol 48:1038-1045.
2. 3 receptor. Pathophysiological significance and therapeutic implications for neurodegenerative disorders. Ann New York Acad Sei 825:11-22.
3. : Studies in human astroglioma cells. Biochem Biophys Res Commun 241:297-304.
4. 2+-ionophore-induced secretion in a rat mast cell line. J Pharmacol Exp Ther 276:837-845.
5. 3 receptor in the airways of allergic rabbits. FASEB J 11:A346.
6. 2B receptor. Mol Pharmacol 52:846-860.
7. 3 adenosine receptors with N-6-(3-iodobenzyl)adenosine-5′-N-methyIuronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circ Res 80:800-809.
8. 3 adenosine receptor agonists. J Med Chem 41:3174-3185.
9. 3 receptors in mastcells. Trends Pharmacol Sei 15:13-14.
10. 3 receptors? J Immunol 158: 5400-5408.
11. 3 receptor activation increases cytosolic calcium concentration via calcium influx in A6 cells. Drug Dev Res 43:62.
12. 2B receptor as part of a search for potent and selective agonists. Nucleosides Nucleotides 17:969-986.
13. Dunwiddie TV Diao LH, Kirn HO, Jiang JL, Jacobson KA. 1997. Activation of hippocampal adenosine A(3) receptors produces a desensilization of A(l) receptor-mediated responses in rat hippocampus. J Neurosci 17:607-614.
14. 3 receptors potentiate hippocampal calcium current by a PKA-dependent/PKC-independent pathway. Neuropharmacology 36:353-362.
15. 3 receptor activation in rats. Eur J Pharmacol 298:293-297.
16. Hannon JP, Bray-French KM, Fozard JR. 1998. Further pharmacological characterization of the adenosine receptor subtype mediating the oxidative burst in human isolated neutrophils. Drug Dev Res 43:214-224.
17. Jacobson KA, Suzuki E 1996. Recent development in selective agonists and antagonists acting at purine and pyrimidine receptors. Drug Dev Res 39:289-300.
18. 3 adenosine receptors: design of selective ligands and therapeutic prospects. Drugs Future 20:689-699.
19. 3 adenosine receptor-selective antagonists. Neuropharmacology 36:1157-1165.
20. Jacobson MA, Chakravarty PK, Johnson RG, Norton R. 1996. Novel non-xanthine selective A3 adenosine receptor antagonists. Drug Dev Res 37:131.
21. 3 adenosine receptor antagonists. J Med Chem 40:2596-2608.
22. 2A-adenosine receptors and biogenic-amine G protein-coupled receptors. J Med Chem 40:2588-2595.
23. 3 adenosine receptor antagonists. J Med Chem 39:2293-2301.
24. 3-adenosine receptors: structure-activity relationships of l,3-dialkylxanthine-7-riboside derivatives. J Med Chem 37:4020-4030.
25. 2A adenosine receptor. J Biol Chem 270:13987-13997.
26. 3 receptor subtype. J Med Chem 39:4142-1148.
27. 3 receptor stimulation inhibits migration of human eosi-nophils. J Leukoc Biol 62:465-168.
28. 3 selective N-alkoxypurines as novel cytokine modulators and neuroprotectants. Drug Dev Res 45:214-221.
29. 3 receptor agonists. Biochem Biophys Res Commun 219:904-910.
30. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, EI Yacoubi M, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G, Pannentier M. 1997. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388:674-678.
31. 3 adenosine receptor antagonists. J Med Chem 41:3186-3201.
32. 3 receptor: sustained cardioprotection. Proc Natl Acad Sei USA 95:6995-6999.
33. 3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol Sei 15:298-306.
34. 3 adenosine receptor with widespread tissue distribution. Mol Pharmacol 44:524-532.
35. 3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc Res 28:1057-1061.
36. Macek TA, Schaffhauser H, Conn PJ. 1998. Protein kinase C and A3 adenosine receptor activation inhibit presynaptic metabotropic glutamate receptor (mGIuR) function and uncouple niGluRs from GTP-binding proteins. J Neurosci 18:6138-6146.
37. 3 receptor. Cancer Res 54:3521-3526.
38. 3 receptor: N-6-2-(4-aminophenyl)ethyladenosine induces bronchospasm in BDE rats by a neurally mediated mechanism involving cells resembling mast cells. J Pharmacol Exp Ther 279:1148-1156.
39. 3 adenosine receptors regulate CI-channels of nonpigmented ciliary epithelial cells. Amer J Physiol, in press.
40. 1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J Med Chem 41:1456-1466.
41. 3 adenosine receptor antagonists: structural homology and receptor docking. J Chem Inf Comput Sei 38:1239-1248.
42. Olah ME, Stiles GL. 1995. Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol 35:581-606.
43. 3 adenosine receptor. Mol Pharmacol 45:978-982.
44. 3 adenosine receptor. J Biol Chem 270:16895-16902,
45. 3 adenosine receptor. J Biol Chem 271:15272-15278.
46. 3-adenosine receptors by selective adenosine derivatives and xanthine-7-ribosides. Dmg Dev Res 44:97-105.
47. 3 adenosine receptors. J Immunol 156:3435-3442.
48. 3 adenosine receptor in embryonic stem cells. Drug Dev Res 37:110.
49. 3 adenosine receptor. Proc Natl Acad Sei USA 90:10365-10369.
50. 2 receptor agonist-induced neurotoxicity in rat cerebellar granule neurons. Drug Dev Res 40:267-273.
51. 125JAB-MECA) labels multiple adenosine receptor subtypes in rat brain. Brain Res 745:10-20.
52. 3 adenosine receptor. Circ Res 78:627-634.
53. 3-adenosine receptors? Drug Dev Res 39:36-16.
54. 3 adenosine receptors agonist. Exp Cell Res 243:383-397.
55. 3 receptors during prolonged simulated ischemia. Am J Physiol 273:11501-H505.
56. 3 receptors. J Clin Invest 98:1773-1779.
57. 3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart. Cardiovasc Res 33:410-415.
58. 3 receptor ligands. II. Structure affinity profile of a series of isoquinoline and quinazolinecompounds. J Med Chem 41:3994-1000.
59. 3 receptor. Drug Dev Res 43:31.
60. 3 receptor stimulation and cerebral-ischemia. Eur J Pharmacol 263:59-67.
61. 3 receptor antagonists and protection against cerebral ischemie damage in gerbils. Soc Neurosci Abstr 23:1924.
62. 3 receptor expression and function in eosinophils. Am J Respir Cell Mol Biol 16:531-537.
63. 3 antagonists. Biochem Biophys Res Commun 232: 317-322.